mAbxience is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $31.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | mAbxience's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Keytruda | Merck | Biosimilar | 2028 | In clinical trials | $31.7B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not mAbxience's share of it.